U. S. regulators Wednesday a booster dose of the COVID-19 vaccine made by Novavax.
The Food and Drug Administration said the new recall option is for other people over the age of 18 who can’t get the updated Pfizer or Moderna boosters targeting omicron for medical or accessibility reasons, or who otherwise wouldn’t get a COVID-19 booster at all.
The FDA clarified that the additional dose of Novavax should be used as a first booster, not for other people who have already received one or more booster doses, at least six months after completing their main injections.
The first two-dose Novavax vaccines have been available since the summer. Novavax is a protein-based vaccine unlike other COVID-19 vaccines available in the United States, adding Pfizer, Moderna or Johnson.
About 48% of Americans who got their number one vaccines never got that first booster.
“Offering a selection of exchange vaccines can increase COVID-19 booster vaccination rates for those adults,” Novavax CEO Stanley Erck said in a statement.
The Centers for Disease Control and Prevention also resolves it after the FDA.
U. S. health officials are not allowed to take care of the U. S. health officials. U. S. officials have encouraged Americans to pick up on updated Pfizer and Moderna to encourage policy against common maximum omicron strains ahead of an expected winter surge.
The new Novavax booster is made with the original formula of this company; He is testing a recipe aimed at Omicron.
___
The Associated Press Department of Health and Science receives from the Howard Hughes Medical Institute’s Department of Science Education. The Palestinian Authority is solely to blame for all the content.
Top headlines via email, mornings of the week
Get the top Union-Tribune headlines in your inbox Monday through Friday mornings, adding the most sensitive news, local, sports, commercial, entertainment and opinion.
You may get promotional content from the San Diego Union-Tribune.
Privacy PolicyTerms of UseSubscribe to our newsletters
To follow